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Abstract
Background: DNA methylation changes are widely used as early molecular markers in cancer detection. Sensitive 
detection and classification of rare methylation changes in DNA extracted from circulating body fluids or complex 
tissue samples is crucial for the understanding of tumor etiology, clinical diagnosis and treatment. In this paper, we 
describe a combined method to monitor the presence of methylated tumor DNA in an excess of unmethylated 
background DNA of non-tumorous cells. The method combines heavy methyl-PCR, which favors preferential 
amplification of methylated marker sequence from bisulfite-treated DNA with a methylation-specific single nucleotide 
primer extension monitored by ion-pair, reversed-phase, high-performance liquid chromatography separation.
Results: This combined method allows detection of 14 pg (that is, four to five genomic copies) of methylated 
chromosomal DNA in a 2000-fold excess (that is, 50 ng) of unmethylated chromosomal background, with an analytical 
sensitivity of > 90%. We outline a detailed protocol for the combined assay on two examples of known cancer markers 
(SEPT9 and TMEFF2) and discuss general aspects of assay design and data interpretation. Finally, we provide an 
application example for rapid testing on tumor methylation in plasma DNA derived from a small cohort of patients 
with colorectal cancer.
Conclusion: The method allows unambiguous detection of rare DNA methylation, for example in body fluid or DNA 
isolates from cells or tissues, with very high sensitivity and accuracy. The application combines standard technologies 
and can easily be adapted to any target region of interest. It does not require costly reagents and can be used for 
routine screening of many samples.
Background
Changes in DNA methylation such as hypermethylation
of tumor suppressor genes are regarded as early molecu-
lar events during cancer development. Such epigenetic
changes are widely used as molecular markers in tumor
cell diagnostics [1-3]. Selective and robust PCR-based
screening methods for very early detection of abnormal
tumor-specific methylation become increasingly impor-
tant. In particular, methods to screen for the low abun-
dance of aberrantly methylated tumor DNA present in
peripheral blood samples or other body fluids are
regarded as very promising, non-invasive, early cancer
detection tests [4].
Although many potentially diagnostic DNA methyla-
tion markers for such sensitive tests have been identified
for several solid tumor types (for example, colon, breast
or prostate cancer) only a few have passed validation tests
in larger clinical studies on blood plasma samples [5-9].
One reason not to gain faster progress in 'biomarker' vali-
dation is the lack of robust and versatile methods for
comprehensive and robust clinical testing. A combination
of real-time PCR using either methylation-specific prim-
ers (MS-PCR)[10] or blockers (heavy methyl-PCR; HM-
PCR) [11] with methylation-specific fluorescence probes
(for example, MethyLight) [12] have successfully been
used to detect low copy numbers of aberrantly methy-
lated tumor DNA in blood plasma samples [12,13]. In this
paper, we present a novel assay combining sensitive HM-
PCR with methylation-restricted single nucleotide
primer extension (MR-SNuPE) followed by ion-pair,
reversed-phase, high-performance liquid chromatogra-
phy IIP/RP-HPLC) detection. The combined assay has
the highest analytical sensitivity, allows an excellent prod-
uct and quality monitoring, and is as sensitive as real-
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time PCR-based assays. Technically the assay is easy to
perform, including semi-automatable processing steps
(see workflow outlined in Figure 1). It requires a HPLC
system but otherwise operates at relatively low cost, as it
does not rely on the use of complex chemistry. We dem-
onstrate the sensitivity and application of the method to
routine diagnostics in a pilot study on two pre-validated
colon cancer methylation markers, transmembrane epi-
dermal growth factor (TMEFF2/TPEF) and septin 9
(SEPT9) [14-18].
Results
We first determined the limits of SNuPE detection by IP/
RP-HPLC on PCR products obtained by conventional
PCR of bisulfite-treated template DNA. We mixed
decreasing amounts of fully methylated template (1:1 to
1:1,000) in an excess of fully unmethylated bisulfite-
treated DNAs. These mixed template DNAs were treated
with bisulfite and then used to generate SEPT9- and
TMEFF2-specific PCR products. Amplicons were subse-
quently treated with an exonuclease I/shrimp alkaline
phosphatase (SAP) mix to remove PCR primers and
dephosphorylate dNTPs, followed by heat inactivation
and direct use of CpG-specific primer extension (see
workflow Figure 1). Primers were designed for both
strands of the PCR products, and extension reactions
were performed with regular unlabelled ddNTPs. For
extension primers we used either the CpG-free (unbiased
recognition of bisulfite DNA; MS-SNuPE)[19] primers
'oligo 27' for SEPT9 and 'oligo 30' for TMEFF2, or the
(methylation-restricted; MR-SNuPE) CpG dinucleotide-
containing primers 'oligo 45' for SEPT9 and 'oligo 62' for
TMEFF2 (top strand) and 'oligo 28' for SEPT9 and 'oligo
44' for TMEFF2 (bottom strand) (Figure 2A; see Addi-
t i o n a l  f i l e  1 ,  s u p p l e m e n t a l  f i g u r e  1 A ) .  S N u P E  r e a c t i o n
products were individually separated on a column
(DNASep™ Cartridge; Transgenomic, Omaha, NE, USA)
using a DNA fragment analyzer (WAVE™ DNA Fragment
Analysis System; Transgenomic). Figure 2B shows the
MS-SNuPE and MR-SNuPE electropherograms obtained
for the SEPT9-specific extensions (primers 27, 28 and
45). Product peaks (ultraviolet spectra at 260 nm) repre-
senting methylated and unmethylated templates (desig-
nated M and UM in the figures) were identified on fully
methylated and unmethylated amplicons, respectively
(Figure 2B (a and b)). We recommend performing such
control reactions to standardize experimental series
because absolute retention times can change depending
on the age of the HPLC column. Moreover, a no-template
control (NTC) was carried along with each MS-SNuPE
and MR-SNuPE reaction to reveal the retention time of
the unextended primer and unspecific primer products
(for example, see oligo 45 in Figure 2B). The incremental
dilutions of methylated templates in an unmethylated
background revealed small but reproducibly detectable
methylation-specific primer extensions even in mixtures
containing only one methylated copy in 100 unmethy-
lated copies (that is, a detection limit of about 1%).
Although the detection of methylation was robust for all
p r i m e r s ,  t h e  p r e s e n c e  o f  u n m e t h y l a t e d  p r o d u c t s  o b v i -
Figure 1 Workflow of the combined heavy methyl (HM)-PCR/
methylation-restricted single nucleotide primer extension (MR-
SNuPE) assay.
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Figure 2 MR-SNuPE assay design for SEPT9 and general performance. (A) SEPT9 amplicon sequence with indicated primer (boxes) and blocker 
(line above) positions. (B) Electropherograms of separated single nucleotide primer extension (SNuPE) products from PCR products obtained without 
blocker on (a) completely methylated and (b) unmethylated DNA templates or (c-f) mixed DNA templates (methylated:unmethylated DNA ratios/
dilution series). (g) Effect when performing a heavy methyl (HM)-PCR; that is, when the blocker is included, on a dilution shown in (f). Vertical dashed 
lines indicate the positions of unextended primer, methylated and unmethylated signals, respectively, NTC = no template control, that is, SNuPE re-
action without PCR template.
A Oligo 27
gattcgttgtttattagttattatgtcggatttcgcggttaacgcgtagttggatgggattattt
ctaagcaacaaataatcaataatacagcctaaagcgccaattgcgcatcaacctaccctaataaa
Oligo 45
gattcgttgtttattagttattatgtcggatttcgcggttaacgcgtagttggatgggattattt
ctaagcaacaaataatcaataatacagcctaaagcgccaattgcgcatcaacctaccctaataaa
Oligo 28
gattcgttgtttattagttattatgtcggatttcgcggttaacgcgtagttggatgggattattt
ctaagcaacaaataatcaataatacagcctaaagcgccaattgcgcatcaacctaccctaataaa
B
UP UM
Oligo 27
M
Oligo 45
UP UM M
Oligo 28
UP UM M
fully methylated
template
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M:UM 1:1
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ously influences the sensitivity and specificity of the reac-
tion. For example, unmethylated extension products were
obtained with oligo 28 and oligo 45, which should only
bind to and extend methylated templates (Figure 2B).
Analogous results were obtained for TMEFF2-specific
reactions (see Additional file 1, supplemental figure 1B).
To suppress unspecific extension and enhance the detec-
tion sensitivity, a PCR blocker (for position within the
PCR products see Figure 2A, Additional file 1, supple-
mental figure 1A) which specifically binds and suppresses
the amplification of unmethylated templates, was
included in the PCR reactions. The presence of this
blocker significantly enhances the enrichment of methy-
lated products. Clear methylation-specific extension
products (designated as M; Figure 2B (g); see Additional
file 1, supplemental figure 1A (g)) were visible down to a
1:1,000 dilution. Nevertheless, the blocker does not com-
pletely suppress the amplification of unmethylated tem-
plates, which could be visualized as primer extension
products when using the oligos 27, 30, 62, 44 and 28,
which produce unmethylated extension products (UM in
the figure). Note that the signals representing unmethy-
lated products for oligo 28 were at least partially caused
by its complementarity to the blocker that is present in
the reaction, hence, the presence of the blocker should be
taken into account when performing primer design.
In summary, the analysis performed on two amplicons
revealed that MR-SNuPE reactions performed on tem-
plates generated by conventional unbiased PCR already
reach high levels of detection, that is, at least one methy-
lated copy could easily and unambiguously be detected in
a background of 1,000 unmethylated copies. However, in
MR-SNuPE reactions, detection of co-methylated tem-
plates is favored because oligos are used that include
CpGs (oligos 28 and 45; oligos 44 and 62). Extension
primers without CpGs (oligos 27 and 30) bind indepen-
dently of the methylation state (MS-SNuPE reaction) and
might not be as sensitive but allow simultaneous detec-
tion of co-amplified non-methylated templates and,
hence, serve as a good HM-PCR (or MS-PCR) quality
control (see below).
To enhance the sensitivity we then combined SNuPE
reactions on PCR products produced by HM-PCR. To
define the limit of detection in such double selective reac-
tions for very low DNA concentrations such as in blood
plasma DNA samples, we again performed a proof of
principle experiment. We spiked defined amounts of
methylated templates (6.25, 12.5, 25, 50 and 100 pg) into
unmethylated background (50 ng) and performed primer
extension reactions on 10 to 24 HM-PCR reactions for
each 'dilution'. For SEPT9 we observed a 100% detection
down to 25 pg of spiked methylated template (corre-
sponding to 1 methylated copy in 500 to 2,000 unmethy-
lated copies) (see Additional file 1, supplemental Figure
2A, supplemental Figure 2B and supplemental table 1). A
detection rate of 83.3% was obtained with 12.5 pg (1 in
4,000) and 58.3% with 6.25 pg (1 in 8,000) methylated
template. Hence, with a 90% probability (Probit analysis),
the method allows detection of 13.6 pg (CI 9.6 to 193 pg)
of methylated copies in an excess of unmethylated back-
ground for SEPT9 and 21.9 pg (CI 13.0 to 36.9 pg) for
TMEFF2 (Additional file 1, supplemental Figure 2C, sup-
plemental Figure 2D). Hence, the combined HM-PCR/
MR-SNuPE assay reaches sensitivities close to the theo-
retical optimum.
In a double-blind study, we then used the combined
HM-PCR/MR-SNuPE assay to detect methylation at
SEPT9 in free-floating tumor DNA isolated from blood
plasma of colon cancer probands. One-fifth of bisulfite-
treated DNA samples isolated from 4-5 ml of plasma
taken from 20 patients with colorectal cancer (CRC) and
20 healthy donors was used for HM-PCR and subsequent
MS-SNuPE and MR-SNuPE. In all 20 healthy donor sam-
ples, only unmethylated products were seen, whereas in
the CRC samples, methylated products were found in 10
of the 20 cases by HM-PCR/primer extension assays
using oligo 27 and oligo 45 (Figure 3). In a real-time cou-
pled HM-PCR assay, 11 of the 20 CRC samples were
found to be methylation-positive (data not shown) [11].
Both methods together detected 13 of 20 cases as methy-
lation-positive, but were discordant for five samples: two
cases were clearly detected by HM-PCR/MR-SNuPE and
not by real-time HM-PCR alone, and the other three
cases were only positive by real-time HM-PCR. When
analyzing the threshold cycles (CT) of the corresponding
real-time PCRs, we observed that methylated DNA
detection was in all cases close to the single copy level in
the respective samples (data not shown). The discordant
detection of five cases is therefore most likely a result of
stochastic PCR variability on extremely low concentra-
tions of methylated DNA in the respective plasma sam-
ples. In fact, both the real-time HM-PCR and the HM-
PCR/SNuPE assays were performed on different aliquots
of the same bisulfite-treated DNA. Thus, we recommend
performing assays in replicates to decrease the number of
false negatives resulting from limited amounts of methy-
lated copies. Overall, our pilot experiment shows that
there is no significant difference in the performance and
sensitivity of both methods (a McNemar test for both
methods on the 20 CRC samples showed a similar perfor-
mance with P = 1.0).
Discussion
By combining two highly selective DNA methylation
enrichment techniques (HM-PCR and MR-SNuPE), we
generated a novel assay with extremely sensitive detec-
tion rates. With this combination, we were able to detect
14 pg methylated template DNA (~ four to five haploidTierling et al. Epigenetics & Chromatin 2010, 3:12
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reached a detection level close to the theoretical limit. We
then performed a small pilot study on plasma DNA sam-
ples from 20 patients with CRC and 20 healthy individu-
als to demonstrate that the method can in principle be
used for routine analysis in biomedical research.
All of the main assays such MS-PCR, MethyLight or
HM-PCR used for the detection of rare methylation in
DNA samples are based on selective bisulfite-PCR ampli-
fication, but differ in the manner of data readout and the
level of sensitivity [20-23]. In comparison to the real-
time-based methods, MethylLight and other HM-PCR-
based assays, the combined HM-PCR/MR-SNuPE is a
simple end-point analysis that is comparable with MS-
PCR but is more sensitive and selective. It does not
require sophisticated chemistry but still achieves an
excellent detection level. Moreover, by using combina-
tions of MS-SNuPE and MR-SNuPE primers, it is possible
to assess several CpG positions independently and also to
quality control the selective methylation-specific PCR
performance (see below). Very recently, another alterna-
tive assay reaching a similar sensitivity was reported.
That method uses heat-stable restriction enzymes during
PCR [24]. By contrast, our method is not limited to the
presence of distinct restriction sites in the amplicon of
interest and, hence, is more flexible in its application. A
further advantage is that it does not require extensive
purification steps or complex and costly nucleotide
chemistry for the analysis.
In our experience, the combination of SNuPE assays
with HM-PCR assays (and presumably MS-PCR also)
requires very little HPLC optimization. However, great
care should be taken with primer design for both MS-
SNuPE and MR-SNuPE reactions. We recommend using
12-16 nucleotides long HPLC-purified oligos. To achieve
the highest selectivity and sensitivity in MR-SNuPE reac-
tions, the oligos should encompass at least three CpG
dinucleotides. In addition, any complementarity with the
blocker used in HM -PCR should be avoided. F or opti-
mum HPLC separation, primers should be generated
from the A-rich strand to generate either ddCTP or
ddTTP extensions. Although the number of methylation-
specific CpG positions in the extension oligos (such as
oligo 45 that includes four CpGs) enhances the specificity
for methylated products only, the detection sensitivity is
equally good with oligos that additionally detect co-
amplified non-methylated templates in the HM-PCR
reaction (see oligo 27 in Figure 2B (g), for example). We
recommend including at least one unbiased (MS-SNuPE)
extension primer (oligos 27 and 30 in our example) in the
as s a y .  T h is  a l l o ws  s i m u l ta n eo us  d e t ect i o n  o f  u n m e t h y-
lated and methylated products, serves as a direct quality
control for the HM-PCR (MS-PCR) amplification, and
Figure 3 Assay performance tested on samples from patients 
with colorectal cancer. Electropherograms after separation of meth-
ylation-restricted single nucleotide primer extension (MR-SNuPE) 
products obtained from plasma taken from patients with colonosco-
py-verified colorectal cancer. Plasma from (a-c) patient with cancer, 
obtained from Proteogenex (PRO6, PRO20) or Oncomatrix (OMA19); 
(d) healthy individual, obtained from Oncomatrix (OMA8). (e) Normal 
blood plasma (5 ml) spiked with 12.5 ng methylated DNA (Chem). 
Peaks were assessed by the relative signal retention times as described 
in the legend to Figure 2. UP = unextended primer, M = methylated 
signal; NTC = SNuPE reaction with water.
UP M UM
Oligo 27 Oligo 45
UP M
cancer 1
Chem
NTC
cancer 2
cancer 3
healthy
a
b
c
d
eTierling et al. Epigenetics & Chromatin 2010, 3:12
http://www.epigeneticsandchromatin.com/content/3/1/12
Page 6 of 8
monitors the accuracy of the SNuPE extension. Besides
the high sensitivity and specificity, the combination of
HM-PCR and SNuPE detection has several practical
advantages for routine sensitive diagnostics. First, the
inclusion of a blocker for unmethylated DNA into the
HM-PCR reaction significantly reduces the amount of
unmethylated byproducts and enhances the sensitivity
and specificity of the SNuPE detection. A similar princi-
ple is used in MS-PCR assays when primers are placed
across several methylated CpG positions [10]. In contrast
to MS-PCR, the use of unbiased primers and the pres-
ence of selective blockers in our assay reduce but do not
eliminate the amplification of unmethylated DNA. More-
over, the assay does not require complete co-methylation
of all CpG positions. Secondly, our approach represents
an all-or-nothing detection, that is, methylated DNA
templates (above the detection threshold) always provide
strong signals/peaks so that misinterpretations (false pos-
itives) can almost invariably be excluded.
Because the detection limit may easily be reached in
plasma DNA samples (as seen in our small study) and
because individual DNA samples might stochastically
vary in the amount of tumor DNA present, the problem
of false negatives has to be considered. We therefore sug-
gest performing reactions in triplicate and, if possible, on
independent DNA isolates and on several genes/ampli-
cons. We are convinced that this robust combined HM-
PCR/MR-SNuPE assay will be a useful diagnostic tool for
the fast and cost-efficient detection of rare DNA methyla-
tion and will be applicable to larger cohort studies.
Conclusions
The described HM-PCR/MR-SNuPE assay is a robust and
versatile endpoint analysis method for high sensitive
detection of rare DNA methylation in complex DNA
samples. The assay is cost-efficient and allows semi-auto-
mated processing of samples, making it applicable for
routine testing in DNA samples isolated from biopsy tis-
sues or body fluids.
Methods
DNA and sample material
Universal in vitro methylated human DNA was obtained
from Millipore. Unmethylated DNA was prepared by
molecular displacement amplification (MDA)[25] of 10
ng peripheral blood leukocyte DNA (Promega, Man-
nheim, Germany) using a commercial kit (Repli-G Kit;
Qiagen, Hilden, Germany). Blood plasma from 20
patients with CRC (stages I, II, III) and 20 colonoscopy-
verified normal controls was obtained from Oncomatrix
and ProteoGenex, where samples were collected after
informed consent and in compliance with local guide-
lines.
Sample preparation
DNA was isolated from 5 ml of blood plasma and bisulfite
converted [26] using previously established procedures
(for detailed information see Additional file 1).
Real-time PCR
HM-PCR was performed in 96-well plates on a thermal
cycler (LightCycler 480; Roche, Mannheim, Germany).
For both SEPT9 and TMEFF2, each 25 μl reaction con-
tained 300 nM each of both forward and reverse primers
(Table 1), 1 μM blocker and 100 nM of probe in 1× buffer
(QuantiTect mPCR Kit NoROX; Qiagen, Hilden, Ger-
many). After 30 minutes at 95°C, 50 cycles of PCR were
performed: 30 seconds at 56°C and 10 seconds at 95°C for
SEPT9; 30 seconds at 56°C, 10 seconds at 72°C, 10 sec-
onds at 95°C for TMEFF2. The mixture was then cooled
to 40°C.
HM-PCR, primer extension and HPLC separation
For methylation analysis by SNuPE, HM-PCR was per-
formed as described above, omitting the probe. An ali-
quot (5 μl) of the HM-PCR product were treated with 1 μl
of Exo-SAP (1:10 mixture of exonuclease I and SAP (USB,
Staufen, Germany) for 30 min at 37°C. To inactivate the
Exo-SAP enzymes, the reaction was incubated for 15
minutes at 80°C. Primer extension was carried out as
described previously[27].
For SEPT9, to the PCR product/Exo-SAP mix, 2 μl of
10× buffer C (Solis BioDyne), 2.4 μl of 30 μM SNuPE
primer (oligos 27, 28 and 45), 1 μl of 1 mM ddCTP and
ddTTP or ddGTP and ddATP, respectively, and 0.5 μl of
Termipol DNA polymerase (5 U/μl, Solis BioDyne) were
added to reach a final volume of 20 μl. Reactions were
performed in a thermal cycler under the following condi-
tions: 96°C for 2 minutes, followed by 50 cycles 96°C for
30 seconds, 50°C for 30 seconds and 60°C for 2 minutes.
Separation of SNuPE products was conducted at 50°C by
continuously mixing buffer B (0.1 M triethylammonium
acetate (TEAA), 25% acetonitrile) to buffer A (0.1 M
TEAA) over 10 minutes, resulting in a buffer B concen-
tration of 28% to 35% for oligo 27, 20% to 27% for oligo
28, and 21% to 27% for oligo 45.
For TMEFF2, To the PCR product. Exo-SAP mix, 2 μl
of 10× buffer C (Solis BioDyne), 2.4 μl of 30 μM SNuPE
primer (oligos 30, 44 and 62), 1 μl of 1 mM ddCTP and
ddTTP or ddGTP and ddATP, respectively, and 0.5 μl of
Termipol (5 U/μl; Solis BioDyne) were added to reach a
final volume of 20 μl. Reactions were performed in a ther-
mal cycler under the following conditions: 96°C for 2
minutes followed by 50 cycles of 96°C for 30 seconds,
60°C for 30 seconds and 60°C for 2 minutes. Separation of
SNuPE products was conducted at 50°C by continuously
mixing buffer B (0.1 M TEAA, 25% acetonitril) to buffer
A (0.1 M TEAA) over 10 minutes, resulting in a buffer BTierling et al. Epigenetics & Chromatin 2010, 3:12
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concentration of 21% to 29% for oligo 30, 16% to 26% for
oligo 44, and 18% to 28% for oligo 62.
Cloning and bisulfite sequencing of methylated and 
unmethylated SEPT9 amplicons
For preparation of methylated and unmethylated SEPT9
amplicons, 5 ng of bisulfite-treated methylated and unm-
ethylated DNA, respectively, were amplified by HM-PCR
without using a probe. PCR products were cloned into
pGemT vector (Promega, Mannheim, Germany) accord-
ing to the manufacturer's protocol, and transformed into
Escherichia coli TOP10 cells. Positive clones were
checked by colony PCR and subsequently sequenced.
Complete unmethylated and methylated clones were
used for HPLC separation.
Limit of detection
In total, 50 ng of bisulfite-treated unmethylated DNA was
spiked with subnanogram amounts (100, 50, 25, 12.5,
6.25, 0 pg) of bisulfite-treated methylated DNA and ana-
lyzed in replicate by both methods in parallel. The limit of
detection was defined as the minimum amount of
bisulfite-treated methylated DNA that could be distin-
guished from unmethylated background with 90% confi-
dence.
Additional material
Additional file 1 Supplementary material.
Table 1: Oligos used in the assays
Gene name Oligo name Sequence 5'T3'
SEPT9 Forward GATT-X-GTTGTTTATTAGTTATTATGT
Reverse AAATAATCCCATCCAACTA
Blocker GTTATTATGTTGGATTTTGTGGTTAATGTGT
AG-C3
Probe FAM-TTAACCGCGAAATCCGAC-BHQ1
Oligo 27 ttattagttattatgt
Oligo 28 cggatttcgcggttaacg
Oligo 45 cgcgttaaccgcgaaatcc
TMEFF2 Forward GGTTATTGTTTGGGTTAATAAATG
Reverse AAAAAAAAAAAACTCCTCTACATAC
Blocker ACATACACCACAAATAAATTACCAAAAAC
ATCAACAA-C3
Probe FAM-TTCGGACGTCGTTGTTCGG-BHQ1
Oligo 30 gttaataaatggagtt
Oligo 44 gaacaacgacgtcc
Oligo 62 cgtcgttgttcggt
X = tetrahydrofuran-type abasic site.Tierling et al. Epigenetics & Chromatin 2010, 3:12
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